Total Payments
$6,244
2024 Payments
$305.49
Companies
31
Transactions
321
Medicare Patients
2,310
Medicare Billing
$192,321
Payment Breakdown by Category
Food & Beverage$6,214 (99.5%)
Other$17.74 (0.3%)
Education$11.71 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $6,214 | 319 | 99.5% |
| Debt forgiveness | $17.74 | 1 | 0.3% |
| Education | $11.71 | 1 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $860.47 | 32 | $0 (2024) |
| ABBVIE INC. | $844.47 | 52 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $593.90 | 27 | $0 (2024) |
| PFIZER INC. | $582.44 | 30 | $0 (2024) |
| Novo Nordisk Inc | $495.11 | 38 | $0 (2024) |
| Lilly USA, LLC | $377.22 | 23 | $0 (2023) |
| GlaxoSmithKline, LLC. | $347.81 | 17 | $0 (2023) |
| SANOFI-AVENTIS U.S. LLC | $324.39 | 13 | $0 (2023) |
| Janssen Pharmaceuticals, Inc | $313.19 | 13 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $256.02 | 14 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $305.49 | 13 | ABBVIE INC. ($85.75) |
| 2023 | $2,021 | 95 | ABBVIE INC. ($389.17) |
| 2022 | $2,002 | 97 | AstraZeneca Pharmaceuticals LP ($268.78) |
| 2021 | $1,916 | 116 | AstraZeneca Pharmaceuticals LP ($202.94) |
All Payment Transactions
321 individual payment records from CMS Open Payments — Page 1 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/09/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $27.76 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/04/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $17.15 | General |
| 09/03/2024 | Baxter Healthcare | — | Debt forgiveness | In-kind items and services | $17.74 | General |
| 07/19/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $17.66 | General |
| Category: Diabetes | ||||||
| 06/17/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $21.67 | General |
| Category: Respiratory | ||||||
| 05/17/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $25.18 | General |
| Category: Cardio-renal | ||||||
| 05/09/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $30.20 | General |
| Category: NEUROSCIENCE | ||||||
| 04/12/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $29.00 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 04/05/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $24.77 | General |
| Category: Respiratory | ||||||
| 03/13/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $26.34 | General |
| Category: NEUROSCIENCE | ||||||
| 02/07/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $29.21 | General |
| Category: NEUROSCIENCE | ||||||
| 01/23/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $23.60 | General |
| Category: Biological | ||||||
| 01/19/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $15.21 | General |
| Category: PAIN | ||||||
| 12/05/2023 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $21.85 | General |
| Category: Respiratory | ||||||
| 11/14/2023 | Sumitomo Pharma America, Inc. | GEMTESA (Drug) | Food and Beverage | In-kind items and services | $27.03 | General |
| Category: UROLOGY | ||||||
| 11/13/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $21.46 | General |
| 11/11/2023 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID, NURTEC ODT | Food and Beverage | In-kind items and services | $23.20 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 11/08/2023 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $22.94 | General |
| Category: PAIN | ||||||
| 11/08/2023 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $19.71 | General |
| Category: NEUROSCIENCE | ||||||
| 11/06/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $20.66 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/03/2023 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $28.87 | General |
| Category: Cardio-renal | ||||||
| 11/01/2023 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $19.20 | General |
| Category: PAIN | ||||||
| 10/30/2023 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $14.88 | General |
| Category: NEUROSCIENCE | ||||||
| 10/27/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $20.36 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/17/2023 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $33.99 | General |
| Category: NEUROSCIENCE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 418 | 636 | $100,107 | $46,233 |
| 2022 | 9 | 502 | 737 | $105,430 | $48,427 |
| 2021 | 12 | 830 | 1,174 | $115,266 | $52,970 |
| 2020 | 10 | 560 | 838 | $110,707 | $44,691 |
Total Patients
2,310
Total Services
3,385
Medicare Billing
$192,321
Procedure Codes
36
All Medicare Procedures & Services
36 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 168 | 337 | $55,942 | $24,347 | 43.5% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 135 | 135 | $26,460 | $14,737 | 55.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 92 | 140 | $15,540 | $6,544 | 42.1% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 12 | 13 | $845.00 | $329.55 | 39.0% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 11 | 11 | $1,320 | $275.64 | 20.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 178 | 394 | $65,404 | $26,926 | 41.2% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 129 | 129 | $25,284 | $14,305 | 56.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 64 | 77 | $8,547 | $3,405 | 39.8% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2022 | 38 | 38 | $3,040 | $2,605 | 85.7% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 38 | 38 | $760.00 | $744.80 | 98.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 16 | 19 | $1,140 | $155.90 | 13.7% |
| 83036 | Hemoglobin a1c level | Office | 2022 | 15 | 16 | $800.00 | $153.54 | 19.2% |
| J1040 | Injection, methylprednisolone acetate, 80 mg | Office | 2022 | 11 | 13 | $195.00 | $92.74 | 47.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 13 | 13 | $260.00 | $39.00 | 15.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 176 | 348 | $57,733 | $25,885 | 44.8% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 139 | 139 | $23,887 | $15,756 | 66.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 96 | 121 | $13,412 | $5,524 | 41.2% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 22 | 22 | $5,588 | $2,094 | 37.5% |
| 90694 | Influenza virus vaccine, quadrivalent (aiiv4), inactivated, adjuvanted, preservative free, for injection into muscle, 0.5 ml dosage | Office | 2021 | 20 | 20 | $1,500 | $1,323 | 88.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 286 | 422 | $8,440 | $1,266 | 15.0% |
| 17000 | Destruction of skin growth | Office | 2021 | 12 | 13 | $1,560 | $319.72 | 20.5% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 14 | 14 | $910.00 | $231.69 | 25.5% |
| G0008 | Administration of influenza virus vaccine | Office | 2021 | 20 | 20 | $246.00 | $213.54 | 86.8% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 18 | 24 | $1,440 | $204.54 | 14.2% |
| J1040 | Injection, methylprednisolone acetate, 80 mg | Office | 2021 | 13 | 14 | $210.00 | $93.73 | 44.6% |
About Gregory Swart, ARNP
Gregory Swart, ARNP is a Nurse Practitioner healthcare provider based in Yakima, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/23/2006. The National Provider Identifier (NPI) number assigned to this provider is 1255352183.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Gregory Swart, ARNP has received a total of $6,244 in payments from pharmaceutical and medical device companies, with $305.49 received in 2024. These payments were reported across 321 transactions from 31 companies. The most common payment nature is "Food and Beverage" ($6,214).
As a Medicare-enrolled provider, Swart has provided services to 2,310 Medicare beneficiaries, totaling 3,385 services with total Medicare billing of $192,321. Data is available for 4 years (2020–2023), covering 36 distinct procedure/service records.
Ad
Practice Information
- Specialty Nurse Practitioner
- Location Yakima, WA
- Active Since 07/23/2006
- Last Updated 07/22/2010
- Taxonomy Code 363L00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1255352183
Products in Payments
- Kerendia (Drug) $593.90
- UBRELVY (Drug) $478.22
- NURTEC ODT (Drug) $473.67
- FARXIGA (Drug) $391.25
- QULIPTA (Drug) $326.43
- ELIQUIS (Drug) $276.71
- Ozempic (Drug) $269.72
- XARELTO (Drug) $263.78
- BREZTRI (Drug) $234.95
- SOLIQUA 100/33 (Biological) $228.21
- TRELEGY ELLIPTA (Drug) $215.72
- JARDIANCE (Drug) $214.85
- FASENRA (Biological) $180.35
- TRULICITY (Drug) $170.71
- Rybelsus (Drug) $166.72
- SHINGRIX (Biological) $118.15
- EMGALITY (Drug) $110.92
- PAXLOVID (Drug) $103.90
- FREESTYLE LIBRE 2 (Device) $103.48
- TOUJEO (Biological) $96.18
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nurse Practitioner Doctors in Yakima
Bonnie Kultgen, Arnp, ARNP
Nurse Practitioner — Payments: $9,178
Nurse Practitioner $9,178
Mr. Jason Berreman, Arnp C, ARNP C
Nurse Practitioner — Payments: $3,228
Nurse Practitioner $3,228
Anne Tweedy, Arnp, ARNP
Nurse Practitioner — Payments: $2,883
Nurse Practitioner $2,883
Tanda Ferguson, Arnp, ARNP
Nurse Practitioner — Payments: $994.79
Nurse Practitioner $994.79
Glenda Garcia, Arnp, ARNP
Nurse Practitioner — Payments: $840.76
Nurse Practitioner $840.76
Mrs. Kaylee Vantrease
Nurse Practitioner — Payments: $833.46
Nurse Practitioner $833.46